Logo image of CANO

CANO HEALTH INC (CANO) Stock Fundamental Analysis

NYSE:CANO - New York Stock Exchange, Inc. - US13781Y2028 - Common Stock - Currency: USD

2.3  -0.05 (-2.13%)

Premarket: 1.17 -1.13 (-49.13%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to CANO. CANO was compared to 103 industry peers in the Health Care Providers & Services industry. CANO has a bad profitability rating. Also its financial health evaluation is rather negative. CANO is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

In the past year CANO has reported negative net income.
In the past year CANO has reported a negative cash flow from operations.
CANO Yearly Net Income VS EBIT VS OCF VS FCFCANO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 -50M -100M -150M -200M

1.2 Ratios

CANO's Return On Assets of -47.69% is on the low side compared to the rest of the industry. CANO is outperformed by 85.22% of its industry peers.
Industry RankSector Rank
ROA -47.69%
ROE N/A
ROIC N/A
ROA(3y)-7.72%
ROA(5y)N/A
ROE(3y)-77.02%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CANO Yearly ROA, ROE, ROICCANO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 -50 -100

1.3 Margins

CANO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CANO Yearly Profit, Operating, Gross MarginsCANO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 -2 -4 -6 -8

0

2. Health

2.1 Basic Checks

CANO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CANO has been reduced compared to 1 year ago.
CANO has a worse debt/assets ratio than last year.
CANO Yearly Shares OutstandingCANO Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 100M 200M 300M
CANO Yearly Total Debt VS Total AssetsCANO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 500M 1B 1.5B 2B

2.2 Solvency

CANO has an Altman-Z score of 0.33. This is a bad value and indicates that CANO is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of CANO (0.33) is worse than 66.09% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z 0.33
ROIC/WACCN/A
WACC5.13%
CANO Yearly LT Debt VS Equity VS FCFCANO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 0 200M 400M 600M 800M 1B

2.3 Liquidity

A Current Ratio of 0.40 indicates that CANO may have some problems paying its short term obligations.
CANO has a Current ratio of 0.40. This is amonst the worse of the industry: CANO underperforms 91.30% of its industry peers.
A Quick Ratio of 0.40 indicates that CANO may have some problems paying its short term obligations.
CANO has a worse Quick ratio (0.40) than 91.30% of its industry peers.
Industry RankSector Rank
Current Ratio 0.4
Quick Ratio 0.4
CANO Yearly Current Assets VS Current LiabilitesCANO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 100M 200M 300M

4

3. Growth

3.1 Past

CANO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -343.95%.
The Revenue has grown by 25.69% in the past year. This is a very strong growth!
The Revenue has been growing by 96.42% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-343.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-299.43%
Revenue 1Y (TTM)25.69%
Revenue growth 3Y96.42%
Revenue growth 5YN/A
Sales Q2Q%18.51%

3.2 Future

The Earnings Per Share is expected to decrease by -50.04% on average over the next years. This is quite bad
Based on estimates for the next years, CANO will show a small growth in Revenue. The Revenue will grow by 2.24% on average per year.
EPS Next Y-1383.78%
EPS Next 2Y-122.5%
EPS Next 3Y-50.04%
EPS Next 5YN/A
Revenue Next Year16.84%
Revenue Next 2Y1.95%
Revenue Next 3Y2.61%
Revenue Next 5Y2.24%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
CANO Yearly Revenue VS EstimatesCANO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 1B 2B 3B
CANO Yearly EPS VS EstimatesCANO Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 0 -50 -100 -150

0

4. Valuation

4.1 Price/Earnings Ratio

CANO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CANO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CANO Price Earnings VS Forward Price EarningsCANO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CANO Per share dataCANO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 200 400

4.3 Compensation for Growth

A cheap valuation may be justified as CANO's earnings are expected to decrease with -50.04% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-122.5%
EPS Next 3Y-50.04%

0

5. Dividend

5.1 Amount

CANO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

CANO HEALTH INC

NYSE:CANO (2/2/2024, 8:04:00 PM)

Premarket: 1.17 -1.13 (-49.13%)

2.3

-0.05 (-2.13%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-09 2023-11-09/amc
Earnings (Next)02-27 2024-02-27/amc
Inst Owners9.13%
Inst Owner Change-0.06%
Ins Owners387.39%
Ins Owner Change0%
Market Cap12.44M
Analysts48.89
Price Target4.85 (110.87%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-357.38%
Min EPS beat(2)-389.24%
Max EPS beat(2)-325.53%
EPS beat(4)2
Avg EPS beat(4)-77.16%
Min EPS beat(4)-389.24%
Max EPS beat(4)402.66%
EPS beat(8)5
Avg EPS beat(8)-55.04%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-4.53%
Min Revenue beat(2)-9.27%
Max Revenue beat(2)0.21%
Revenue beat(4)3
Avg Revenue beat(4)-0.46%
Min Revenue beat(4)-9.27%
Max Revenue beat(4)5.3%
Revenue beat(8)4
Avg Revenue beat(8)-4.42%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)295.83%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-3.5%
EPS NY rev (1m)0%
EPS NY rev (3m)-15217%
Revenue NQ rev (1m)-0.06%
Revenue NQ rev (3m)-0.37%
Revenue NY rev (1m)-0.19%
Revenue NY rev (3m)0.5%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-115.87
EYN/A
EPS(NY)-38.06
Fwd EYN/A
FCF(TTM)-32.43
FCFYN/A
OCF(TTM)-27.14
OCFYN/A
SpS573.4
BVpS-22.57
TBVpS-173.79
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -47.69%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-7.72%
ROA(5y)N/A
ROE(3y)-77.02%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover2.56
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 26.58%
Cap/Sales 0.92%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.4
Quick Ratio 0.4
Altman-Z 0.33
F-Score2
WACC5.13%
ROIC/WACCN/A
Cap/Depr(3y)63.12%
Cap/Depr(5y)N/A
Cap/Sales(3y)1.8%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-343.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-299.43%
EPS Next Y-1383.78%
EPS Next 2Y-122.5%
EPS Next 3Y-50.04%
EPS Next 5YN/A
Revenue 1Y (TTM)25.69%
Revenue growth 3Y96.42%
Revenue growth 5YN/A
Sales Q2Q%18.51%
Revenue Next Year16.84%
Revenue Next 2Y1.95%
Revenue Next 3Y2.61%
Revenue Next 5Y2.24%
EBIT growth 1Y-134.01%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-168.37%
EBIT Next 3Y43.75%
EBIT Next 5Y35.27%
FCF growth 1Y-48.26%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-54.37%
OCF growth 3YN/A
OCF growth 5YN/A